Business
Scancell to present at 2025 AACR Annual Meeting
Scancell to present at 2025 AACR Annual Meeting.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n\n1 April 2025\n \nScancell Holdings plc\n(\"Scancell\" or the \"Company\")\n \nScancell to Present Clinical Data from the Ongoing Phase 2 SCOPE Trial of SCIB1 at 2025 AACR Annual Meeting\n \nScancell Holdings plc (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, today announce clinical data from the ongoing Phase 2 SCOPE trial will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in Chicago, Illinois on 25-30 April 2025.\n \nSCIB1 is a potent, targeted DNA melanoma cancer vaccine, that effectively activates high-avidity T cells, leading to a potent, lasting immune response by creating an immune memory that prevents the cancer from recurring.\n \nThe SCOPE study (NCT04079166) is a Phase 2, Multicentre Open-Label, Study, investigating SCIB1/ iSCIB1+, with double checkpoint inhibitors (\"CPIs\") in late-stage melanoma. The first cohort includes 43 patients receiving SCIB1 in combination with ipilimumab and nivolumab. Initial data in 25 patients has shown\n· 84% disease control rate;\n· 80% progression free survival, with 20% complete response rate; and\n· 72% objective response rate.\n \nScancell CMO Nermeen Varawalla will present the SCOPE clinical trial program, preliminary results of cohort 1 and their correlation with T cell responses. These data along with those expected from ongoing study cohorts, 3 & 4 will determine the design for the planned follow-on randomised registration clinical trial. \n \nThe AACR conference is an internationally recognised annual meeting, bringing together world-leading experts to share the latest advances in oncology.\n \nPhil L'Huillier, Chief Executive Officer, Scancell, commented: \"We are excited to share these SCOPE trial results with the scientific community at AACR. The strong disease control and response rate, with an excellent safety profile reinforces the potential of our vaccine to transform melanoma treatment. Our next generation vaccine iSCIB1+ is also being evaluated in a broader patient population within other cohorts of the study. The findings from the overall study will inform the design of our planned global randomized control registration trial...